Evaluation of the effect of oral eplerenone in the management of Acute Central Serous Chorioretinopathy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220423054621N1

Enrollment

Registered

2024-06-24

Start date

2024-06-29

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Central Serous Chorioretinopathy. Separation of retinal layers

Interventions

Intervention 1: Intervention group: Patients in the case group will be treated with eplerenone oral tablets, at the rate of 50 mg per day for 12 weeks. Follow-up of patients in 1, 2, 3 months after th

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of acute central serous chorioretinopathy before twelve weeks Diagnosis of acute central serous chorioretinopathy for the first time

Exclusion criteria

Exclusion criteria: Chronic CSCR (duration of visual symptoms more than 12 weeks) Recurrent CSCR (patients with a history of one or more previous CSCR attacks) Choroidal neovascularization (CNV) detected by FA, ??ICGA, or OCT angiography (OCT-A) Any treatment for retinal disease (including intravitreal injections, photodynamic therapy, laser photocoagulation, vitrectomy) History of other retinal disorders (including age-related macular degeneration, choroidal neovascularization, diabetic retinopathy, uveitis, or pathological myopia) The presence of any other systemic disease for which eplerenone is contraindicated (such as severe renal, cardiac or hepatic failure, pregnancy, baseline serum potassium more than 0.5 mEq/L simultaneous administration of potassium-sparing diuretics, potassium supplements, inhibitors angiotensin converting enzyme or angiotensin receptor blockers)

Design outcomes

Primary

Measure	Time frame
Best corrected visual acuity (BCVA). Timepoint: At the beginning of the study, one month, two months and three months later. Method of measurement: Tumbling E” eye chart.;Central Macular Thickness (CMT). Timepoint: At the beginning of the study, one month, two months and three months later. Method of measurement: Use of SD-OCT device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMona Alvandimanesh

Bagheiat-allah University of Medical Sciences

Monaalvandimanesh@gmail.com+98 921 241 8042

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026